Spots Global Cancer Trial Database for ipatasertib
Every month we try and update this database with for ipatasertib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | NCT03280563 | Breast Neoplasm... | Atezolizumab (M... Bevacizumab Entinostat Exemestane Fulvestrant Ipatasertib Tamoxifen Abemaciclib | 18 Years - | Hoffmann-La Roche | |
| Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients | NCT04253561 | Metastatic Brea... | Ipatasertib Trastuzumab Pertuzumab | 18 Years - | SOLTI Breast Cancer Research Group | |
| Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck | NCT05172258 | Head and Neck S... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Oral... Metastatic Orop... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha... | Biopsy Biospecimen Col... Computed Tomogr... Ipatasertib Pembrolizumab | 18 Years - | National Cancer Institute (NCI) | |
| Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy | NCT01485861 | Prostate Cancer | Abiraterone Apitolisib Ipatasertib Placebo Prednisone Prednisolone | 18 Years - | Genentech, Inc. | |
| Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy | NCT05180006 | Breast Cancer | Atezolizumab In... Bevacizumab Pertuzumab Trastuzumab | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer | NCT05172245 | Clinical Stage ... Head and Neck C... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Maxillary Sinus... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage III Sinon... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Oroph... Stage IVA Sinon... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Lip a... Stage IVB Oroph... Stage IVB Sinon... | Biopsy Biospecimen Col... Cisplatin Computed Tomogr... Ipatasertib Magnetic Resona... Positron Emissi... Radiation Thera... | 18 Years - | National Cancer Institute (NCI) | |
| Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor | NCT04650581 | Breast Cancer | Ipatasertib Fulvestrant Placebo | 18 Years - | Canadian Cancer Trials Group | |
| A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) | NCT03337698 | Carcinoma, Non-... | Atezolizumab Cobimetinib RO6958688 Docetaxel CPI-444 Pemetrexed Carboplatin Gemcitabine Linagliptin Tocilizumab Ipatasertib Bevacizumab Sacituzumab Gov... Radiation Evolocumab Tiragolumab XL092 Camonsertib | 18 Years - | Hoffmann-La Roche | |
| Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial | NCT05554380 | Locally Advance... Metastatic Mali... Unresectable Ma... | Biopsy Biospecimen Col... Computed Tomogr... Ipatasertib Magnetic Resona... Paclitaxel | 18 Years - | National Cancer Institute (NCI) | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | NCT05564377 | Advanced Malign... Anatomic Stage ... Anatomic Stage ... Locally Advance... Malignant Femal... Metastatic HER2... Metastatic Mali... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Unresectable HE... Unresectable Ma... | Alpelisib Binimetinib Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Echocardiograph... Fluorouracil Fulvestrant Ipatasertib Leucovorin Magnetic Resona... Multigated Acqu... Mutation Carrie... Neratinib Malea... Nilotinib Hydro... Olaparib Oxaliplatin Paclitaxel Palbociclib Panitumumab Positron Emissi... Selumetinib Sul... Sotorasib | - | National Cancer Institute (NCI) | |
| A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. | NCT03840200 | Breast Cancer Prostate Cancer Ovarian Cancer | Ipatasertib Rucaparib | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC). | NCT04404140 | Castration-Resi... | Ipatasertib Atezolizumab Docetaxel | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response | NCT04632992 | Advanced Unrese... | Entrectinib Inavolisib Alectinib Ipatasertib Atezolizumab Trastuzumab Emt... Pertuzumab, Tra... Tucatinib Investigator's ... Paclitaxel Tiragolumab Pralsetinib | 18 Years - | Genentech, Inc. | |
| A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC). | NCT04404140 | Castration-Resi... | Ipatasertib Atezolizumab Docetaxel | 18 Years - | Hoffmann-La Roche | |
| A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | NCT04486352 | Endometrial Can... | Atezolizumab - ... Bevacizumab Ipatasertib Talazoparib Trastuzumab emt... Tiragolumab Atezolizumab - ... Inavolisib Letrozole Giredestrant Abemaciclib | 18 Years - | Alliance Foundation Trials, LLC. | |
| Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC | NCT05498896 | Triple Negative... | Atezolizumab Ipatasertib Paclitaxel Doxorubicin Cyclophosphamid... | 18 Years - | Queen Mary University of London | |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | NCT04802759 | Inoperable, Loc... | Giredestrant Abemaciclib Ipatasertib Inavolisib Ribociclib Everolimus Samuraciclib PH FDC SC Palbociclib Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K) | NCT06400251 | Advanced Lympho... Advanced Malign... Refractory Lymp... Refractory Mali... Refractory Mult... | Biopsy Biospecimen Col... Computed Tomogr... Ipatasertib Magnetic Resona... | 18 Years - | National Cancer Institute (NCI) | |
| Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC | NCT05498896 | Triple Negative... | Atezolizumab Ipatasertib Paclitaxel Doxorubicin Cyclophosphamid... | 18 Years - | Queen Mary University of London | |
| A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC). | NCT04404140 | Castration-Resi... | Ipatasertib Atezolizumab Docetaxel | 18 Years - | Hoffmann-La Roche | |
| Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer | NCT05276973 | Fallopian Tube ... Fallopian Tube ... Ovarian Endomet... Ovarian High Gr... Primary Periton... Primary Periton... Stage III Fallo... Stage III Ovari... Stage III Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Unresectable Fa... Unresectable Fa... Unresectable Ov... Unresectable Ov... Unresectable Pr... Unresectable Pr... | Biopsy Carboplatin Ipatasertib Paclitaxel | 18 Years - | National Cancer Institute (NCI) | |
| Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors | NCT01362374 | Neoplasms | 5-FU Docetaxel Enzalutamide Ipatasertib Leucovorin Oxaliplatin Paclitaxel | 18 Years - | Genentech, Inc. | |
| A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors. | NCT04341259 | Solid Tumors | Ipatasertib | 18 Years - | Hoffmann-La Roche | |
| Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer | NCT04737109 | Castrate Resist... | Ipatasertib Darolutamide Androgen Depriv... | 18 Years - | Big Ten Cancer Research Consortium | |
| A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors | NCT01562275 | Neoplasms | Ipatasertib Cobimetinib | 18 Years - | Genentech, Inc. | |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | NCT03424005 | Breast Cancer | Capecitabine Atezolizumab Ipatasertib SGN-LIV1A Bevacizumab Chemotherapy (G... Selicrelumab Tocilizumab Nab-Paclitaxel Sacituzumab Gov... Abemaciclib Fulvestrant Ribociclib Inavolisib Inavolisib (9 m... Inavolisib (6 m... Trastuzumab Der... | 18 Years - | Hoffmann-La Roche | |
| Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor | NCT04650581 | Breast Cancer | Ipatasertib Fulvestrant Placebo | 18 Years - | Canadian Cancer Trials Group | |
| Pre-operative Immunotherapy Combination Strategies in Breast Cancer | NCT03395899 | Breast Cancer Estrogen Recept... | Atezolizumab Cobimetinib Ipatasertib Bevacizumab | 18 Years - | Queen Mary University of London | |
| Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck | NCT05172258 | Head and Neck S... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Oral... Metastatic Orop... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha... | Biopsy Biospecimen Col... Computed Tomogr... Ipatasertib Pembrolizumab | 18 Years - | National Cancer Institute (NCI) | |
| A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | NCT04931342 | Ovarian Cancer | Ipatasertib Cobimetinib Trastuzumab Emt... Atezolizumab Bevacizumab Paclitaxel Giredestrant Abemaciclib Inavolisib Palbociclib Letrozole Olaparib Luteinizing Hor... Cyclophosphamid... Inavolisib | 18 Years - | Hoffmann-La Roche | |
| AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) | NCT03959891 | Breast Cancer | Ipatasertib Fulvestrant Aromatase Inhib... Palbociclib | 18 Years - | Massachusetts General Hospital | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | NCT02465060 | Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ... | Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib | 18 Years - | National Cancer Institute (NCI) | |
| A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site | NCT03498521 | Cancer of Unkno... | Alectinib Vismodegib Ipatasertib Olaparib Erlotinib Bevacizumab Vemurafenib Cobimetinib Trastuzumab Sub... Pertuzumab Atezolizumab Carboplatin Paclitaxel Cisplatin Gemcitabine Entrectinib Ivosidenib Pemigatinib | 18 Years - | Hoffmann-La Roche | |
| Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | NCT04589845 | Solid Tumors | Entrectinib Entrectinib Alectinib Atezolizumab Ipatasertib Trastuzumab emt... Idasanutlin Inavolisib Belvarafenib Pralsetinib GDC-6036 Camonsertib | - | Hoffmann-La Roche | |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | NCT03424005 | Breast Cancer | Capecitabine Atezolizumab Ipatasertib SGN-LIV1A Bevacizumab Chemotherapy (G... Selicrelumab Tocilizumab Nab-Paclitaxel Sacituzumab Gov... Abemaciclib Fulvestrant Ribociclib Inavolisib Inavolisib (9 m... Inavolisib (6 m... Trastuzumab Der... | 18 Years - | Hoffmann-La Roche | |
| Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers | NCT05538897 | FIGO Grade 1 En... FIGO Grade 2 En... Metastatic Endo... Recurrent Endom... Stage IV Uterin... | Biospecimen Col... Computed Tomogr... Ipatasertib Magnetic Resona... Megestrol Aceta... | 18 Years - | National Cancer Institute (NCI) | |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | NCT04591431 | Breast Cancer Gastrointestina... Non Small Cell ... Other Cancer | Erlotinib Trastuzumab Trastuzumab emt... Pertuzumab Lapatinib Everolimus Vemurafenib Cobimetinib Alectinib Brigatinib Palbociclib Ponatinib Vismogedib Itacitinib Ipatasertib Entrectinib Atezolizumab Nivolumab Ipilimumab Pemigatinib Oncology Drugs Pralsetinib Selpercatinib Talazoparib Tepotinib Alpelisib | 18 Years - | Fondazione per la Medicina Personalizzata | |
| A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer | NCT03800836 | Breast Cancer | Ipatasertib Paclitaxel Atezolizumab Nab-Paclitaxel AC | 18 Years - | Hoffmann-La Roche | |
| To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer | NCT04561817 | Ovarian Neoplas... | Ipatasertib Paclitaxel | 18 Years - 90 Years | Icahn School of Medicine at Mount Sinai | |
| A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer | NCT02301988 | Breast Cancer | Ipatasertib Paclitaxel Placebo | 18 Years - | Genentech, Inc. | |
| A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer | NCT01896531 | Gastric Cancer | 5-Fluorouracil Ipatasertib Leucovorin Oxaliplatin Placebo | 18 Years - | Genentech, Inc. | |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | NCT04802759 | Inoperable, Loc... | Giredestrant Abemaciclib Ipatasertib Inavolisib Ribociclib Everolimus Samuraciclib PH FDC SC Palbociclib Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer | NCT03853707 | Anatomic Stage ... Metastatic Trip... Prognostic Stag... | Atezolizumab Capecitabine Carboplatin Ipatasertib Paclitaxel Quality-of-Life... Questionnaire A... | 18 Years - | City of Hope Medical Center | |
| A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors | NCT01562275 | Neoplasms | Ipatasertib Cobimetinib | 18 Years - | Genentech, Inc. | |
| To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer | NCT04561817 | Ovarian Neoplas... | Ipatasertib Paclitaxel | 18 Years - 90 Years | Icahn School of Medicine at Mount Sinai | |
| A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response | NCT04632992 | Advanced Unrese... | Entrectinib Inavolisib Alectinib Ipatasertib Atezolizumab Trastuzumab Emt... Pertuzumab, Tra... Tucatinib Investigator's ... Paclitaxel Tiragolumab Pralsetinib | 18 Years - | Genentech, Inc. | |
| Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | NCT04589845 | Solid Tumors | Entrectinib Entrectinib Alectinib Atezolizumab Ipatasertib Trastuzumab emt... Idasanutlin Inavolisib Belvarafenib Pralsetinib GDC-6036 Camonsertib | - | Hoffmann-La Roche | |
| Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy | NCT05180006 | Breast Cancer | Atezolizumab In... Bevacizumab Pertuzumab Trastuzumab | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | NCT03280563 | Breast Neoplasm... | Atezolizumab (M... Bevacizumab Entinostat Exemestane Fulvestrant Ipatasertib Tamoxifen Abemaciclib | 18 Years - | Hoffmann-La Roche | |
| Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor | NCT04650581 | Breast Cancer | Ipatasertib Fulvestrant Placebo | 18 Years - | Canadian Cancer Trials Group | |
| A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors | NCT02162719 | Breast Neoplasm... | Ipatasertib Paclitaxel Placebo | 18 Years - | Genentech, Inc. | |
| Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer | NCT04464174 | Triple Negative... | Ipatasertib Capecitabine Eribulin Carboplatin Gemcitabine | 18 Years - | MedSIR | |
| A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study | NCT05862285 | Cancer | Ipatasertib Tiragolumab Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| CRAFT: The NCT-PMO-1602 Phase II Trial | NCT04551521 | Metastatic or L... | Vemurafenib Cobimetinib Atezolizumab Trastuzumab Pertuzumab Alectinib Ipatasertib Atezolizumab Atezolizumab Atezolizumab Inavolisib | 18 Years - | German Cancer Research Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
